President and Chief Executive Officer · CRESCENT BIOPHARMA, INC. (CBIO)

Harout Semerjian

A named executive officer of CRESCENT BIOPHARMA in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,389,418

Salary $638,405Stock awards $0Bonus $100,000

FY2022: $1,434,922

1st of 3 named executive officers at Crescent Biopharma by FY2023 total.

3 named officers on file for CRESCENT BIOPHARMA, FY2023

Harout Semerjian’s pay file — $29

  • 3 fiscal years of pay, line by line
  • CBIO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CRESCENT BIOPHARMA’s whole pay program stands against its peers

  • CRESCENT BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 1, 2024 (DEF 14A).

Free

Get Harout Semerjian’s full pay file as a PDF — free

More than this page: up to 10 years of Harout’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Harout Semerjian compensation by year

CRESCENT BIOPHARMA Summary Compensation Table · all 3 fiscal years held
In US dollars, as CRESCENT BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$243,721$614,090$638,405
Bonus$100,000$100,000$100,000
Stock awards$0$0$0
Option awards$2,394,160$338,800$1,263,328
Non-equity incentive$129,537$372,574$376,910
Pension and deferred compensation$0$0$0
All other$8,700$9,458$10,775
Total$2,876,118$1,434,922$2,389,418

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRESCENT BIOPHARMA, INC. DEF 14A filed April 1, 2024, accession 0001558370-24-004448, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CRESCENT BIOPHARMA, INC. filed document, accession 0001558370-24-004448. Every figure is read from that document and cited to the page and table it appears in. Filed April 1, 2024.

$2.9M
$1.4M
$2.4M
FY21
FY22
FY23
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option457,666—$2.03
Option549,200—$2.03
Option220,572—$1.11
Option651,200—$2.55

Per the Outstanding Equity Awards at Fiscal Year-End table in CRESCENT BIOPHARMA, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

CRESCENT BIOPHARMA’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Harout Semerjian · this pagePresident and Chief Executive Officer$2,389,418
Brian HahnChief Financial Officer and Senior Vice President$1,299,939
Edwin RockChief Medical Officer and Senior Vice President$1,152,311

Board service

CRESCENT BIOPHARMA board · FY2023

How this board is paid

Company policy: CRESCENT BIOPHARMA pays directors a $40,000 cash retainer. As stated in CRESCENT BIOPHARMA's FY2023 proxy.

The full CRESCENT BIOPHARMA compensation record

free company brief

This page is one person within CRESCENT BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRESCENT BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Harout Semerjian's compensation dossier · One-time report. No refunds.